DK0832211T3 - Oligonucleotider, der er specifikke for hepatitis B-virus. - Google Patents

Oligonucleotider, der er specifikke for hepatitis B-virus.

Info

Publication number
DK0832211T3
DK0832211T3 DK96918671T DK96918671T DK0832211T3 DK 0832211 T3 DK0832211 T3 DK 0832211T3 DK 96918671 T DK96918671 T DK 96918671T DK 96918671 T DK96918671 T DK 96918671T DK 0832211 T3 DK0832211 T3 DK 0832211T3
Authority
DK
Denmark
Prior art keywords
hepatitis
virus
oligonucleotides specific
hbv
kits
Prior art date
Application number
DK96918671T
Other languages
Danish (da)
English (en)
Inventor
Robert E Kilkuskie
John Goodchild
Charles J Craig
Bruce L Frank
Raymond Jupp
John S Mills
Noel A Roberts
Peter C Roberts
Andrew Slade
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of DK0832211T3 publication Critical patent/DK0832211T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK96918671T 1995-06-06 1996-06-04 Oligonucleotider, der er specifikke for hepatitis B-virus. DK0832211T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46739795A 1995-06-06 1995-06-06
PCT/EP1996/002432 WO1996039502A1 (en) 1995-06-06 1996-06-04 Oligonucleotides specific for hepatitis b virus

Publications (1)

Publication Number Publication Date
DK0832211T3 true DK0832211T3 (da) 2003-05-26

Family

ID=23855522

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96918671T DK0832211T3 (da) 1995-06-06 1996-06-04 Oligonucleotider, der er specifikke for hepatitis B-virus.

Country Status (10)

Country Link
US (2) US5856459A (de)
EP (1) EP0832211B1 (de)
AT (1) ATE233318T1 (de)
AU (1) AU6125296A (de)
CA (1) CA2226458A1 (de)
DE (1) DE69626393T2 (de)
DK (1) DK0832211T3 (de)
ES (1) ES2188760T3 (de)
WO (1) WO1996039502A1 (de)
ZA (1) ZA964445B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040054156A1 (en) * 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
PT952982E (pt) 1996-10-31 2004-03-31 Biogen Inc Novos inibidores da hepatite b
CN1057302C (zh) * 1997-08-27 2000-10-11 中国科学院上海生物化学研究所 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸
CN1215058A (zh) 1997-10-21 1999-04-28 中国科学院上海生物化学研究所 新的三链形成寡核苷酸结构及其在抗乙肝病毒中的应用
WO2000032625A1 (en) 1998-12-04 2000-06-08 Biogen, Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
AU2001254670A1 (en) * 2000-03-02 2001-09-12 Akzo Nobel N.V. Detection of hepatitis b virus rna
US6583279B1 (en) 2001-01-26 2003-06-24 Becton, Dickinson And Company Sequences and methods for detection of hepatitis B virus
EP1383782A1 (de) * 2001-03-26 2004-01-28 Sirna Therpeutics, Inc. Oligonukleotidvermittelte inhibierung der replikation des hepatitis--b-virus und des hepatitis-c-virus
WO2002092006A2 (en) * 2001-05-16 2002-11-21 Micrologix Biotech, Inc. Nucleic acid-based compounds and methods of use thereof
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
ES2370169T3 (es) * 2002-06-14 2011-12-13 Gen-Probe Incorporated Composiciones y métodos para detectar el virus de la hepatitis b.
EP1403385A1 (de) * 2002-09-27 2004-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methode zur Darstellung der Replikation von HBV und zum Testen der Sensibilität von Wirkstoffen
US7998492B2 (en) * 2002-10-29 2011-08-16 Coley Pharmaceutical Group, Inc. Methods and products related to treatment and prevention of hepatitis C virus infection
WO2011047312A1 (en) 2009-10-16 2011-04-21 Glaxo Group Limited Hbv antisense inhibitors
SI3505528T1 (sl) * 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
US8809293B2 (en) * 2011-06-30 2014-08-19 Arrowhead Madison Inc. Compositions and methods for inhibiting gene expression of hepatitis B virus
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
CA2991639A1 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
WO2019240503A1 (ko) * 2018-06-12 2019-12-19 주식회사 에이엠사이언스 B형 간염 예방 또는 치료용 조성물
WO2019240504A1 (en) * 2018-06-12 2019-12-19 Am Sciences Co., Ltd. Modified oligonucleotides for inhibition of target gene expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
EP0554376A4 (en) * 1990-10-22 1994-08-24 Fox Chase Cancer Center Dna construct for providing rna therapy
EP0666923A1 (de) * 1991-09-05 1995-08-16 The University Of Connecticut Gezielte bereitstellung von poly- oder oligonukleotiden in zellen
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
JPH09507062A (ja) * 1993-12-23 1997-07-15 アポロン インク． 抗ｂ型肝炎ウイルスオリゴヌクレオチド
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication

Also Published As

Publication number Publication date
ZA964445B (en) 1996-12-06
ATE233318T1 (de) 2003-03-15
US5856459A (en) 1999-01-05
CA2226458A1 (en) 1996-12-12
EP0832211B1 (de) 2003-02-26
WO1996039502A1 (en) 1996-12-12
DE69626393T2 (de) 2003-12-04
AU6125296A (en) 1996-12-24
US6984729B1 (en) 2006-01-10
DE69626393D1 (de) 2003-04-03
EP0832211A1 (de) 1998-04-01
ES2188760T3 (es) 2003-07-01

Similar Documents

Publication Publication Date Title
DK0832211T3 (da) Oligonucleotider, der er specifikke for hepatitis B-virus.
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
ATE289519T1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen
NO983716D0 (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
DK0821690T3 (da) Nukleotidanaloger til behandling af virusinfektioner
DE68925278D1 (de) Hemmung von htlv-iii durch exogene oligonukleotide
DE69803391D1 (de) Zusammensetzung die mindestens ein doppel strangiges rna und mindestens ein interferon enthält, zur behandlung von virale hepatitis
DE69434931D1 (de) Methode zur selektiven inaktivierung der viralen replication
DE69330372D1 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
TR200003036T2 (tr) 12,13-Modifiye edilmiş epotilon türevleri
ES2196181T3 (es) Derivados de purina y proceso para su preparacion.
DK0966447T3 (da) Anvendelige små molekyler til behandling af betændelsessygdomme
DE69940371D1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
MA24484A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant .
DE60001770D1 (de) Verfahren zur Herstellung von eigenleitfähigen Copolymeren und damit hergestellte eigenleitfähige Copolymer-Verbindungen
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
DE69831000D1 (de) Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch
ATE173466T1 (de) Verbindungen und methoden zur inhibition von hiv und verwandten viren
ATE339211T1 (de) L-fmau zur behandlung von hepatitis-delta-virus- infizierung
ES2091928T3 (es) Metodos de prevencion de la replicacion virica.
EP1331267A3 (de) Spezifische Oligonukleotide für Hepatitis C-Virus
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
WO1996039501A3 (en) Oligonucleotides specific for human papillomavirus